The Competition and Markets Authority (CMA) has issued fines as a result of their nortriptyline investigation. Nortriptyline is an unbranded, prescription-only generic medicine used for the relief of symptoms of depression. In some cases, it can be used to treat neuropathic pain and nocturnal enuresis (bed-wetting).<\/p>\n
The CMA<\/strong> <\/a>has recently issued decisions imposing fines on suppliers of nortriptyline tablets for reportedly breaching competition law<\/strong><\/a> after their nortriptyline investigation concluded. There have also been director disqualifications.<\/p>\n <\/p>\n In September 2019, the CMA announced<\/strong><\/a> that King Pharmaceuticals Limited and Alissa Healthcare Research Limited had admitted infringing competition law<\/strong><\/a> by exchanging \u201ccommercially sensitive information<\/em>\u201d in relation to the supply of 10mg and 25mg nortriptyline tablets.<\/p>\n The Statement of Objections also alleged that King and Auden McKenzie participated in a market sharing infringement in relation to the supply of 10mg and 25mg nortriptyline tablets, and the CMA\u2019s nortriptyline investigation with regard to this infringement remains ongoing.<\/p>\n The CMA can, and is able to, make applications to the court where they can force through the disqualification of a company director. This can affect a person\u2019s ability to be a director and holding directorship roles, and performing certain roles in general. This can then be enforced for a particular period of time.<\/p>\n This can be imposed if a company or a person is found to be in breach of competition law, and can be allowed in accordance with the Company Directors Disqualification Act.<\/p>\n On the 1st<\/sup> June 2020, the CMA reportedly obtained a legal undertaking in relation to Mr Amit Patel, who was a former director of Auden McKenzie (Pharma Division) Limited and Auden McKenzie Holdings Limited. This undertaking reportedly disqualifies him from acting as a director for any company in the UK for a period of five years from 13th<\/sup> July 2020, according to the CMA.<\/p>\nThe CMA\u2019s 2019 Settlement<\/strong><\/h3>\n
Director disqualifications<\/strong><\/h3>\n